SCHEMBL1764883

SCHEMBL1764883

N#Cc1ccc(Oc2ccccc2C=O)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.66
GAA P10253 2/20 0.66
KMT2A Q03164 2/20 0.66
ALDH1A1 P00352 5/20 0.63
CYP1A2 P05177 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
NPSR1 Q6W5P4 1/20 0.53
SLC6A4 P31645 1/20 0.50
HTT P42858 2/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
POLB P06746 2/20 0.42
PARP15 Q460N3 1/20 0.42
PARP10 Q53GL7 1/20 0.42
PARP2 Q9UGN5 1/20 0.42
MAPT P10636 2/20 0.42
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7337144 0.86 LMNA (0.53) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL31599176 0.86 LMNA (0.88) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL7700911 0.82 SLC6A4 (0.62) LMNAGAAKMT2AALDH1A1SLC6A4
SCHEMBL276089 0.81 TBXA2R (0.45) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL2989756 0.81 SLC6A4 (0.43) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL5037397 0.81 LMNA (0.57) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL31241187 0.80 LMNA (0.92) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL95238 0.80 LMNA (1.00) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL3421695 0.80 SLC6A4 (0.60) LMNAGAAKMT2AALDH1A1SLC6A4
SCHEMBL29361707 0.80 LMNA (1.00) LMNAGAAKMT2AALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102753538-B Sultam derivatives HOFFMANN LA ROCHE 2015-04-08 CN disclosed
EP-2504324-B1 SULTAM DERIVATIVES HOFFMANN LA ROCHE (CH) 2015-02-25 EP disclosed
US-20140121213-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2014-05-01 US disclosed
US-20140121213-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2014-05-01 US disclosed
US-20130023541-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED 2013-01-24 US disclosed
US-20130023541-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED 2013-01-24 US disclosed
US-8314250-B2 Sultam derivatives HOFFMANN-LA ROCHE INC. (US) 2012-11-20 US disclosed
EP-2504324-A1 SULTAM DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-10-03 EP disclosed
WO-2011064141-A1 SULTAM DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-03 WO disclosed
US-20110124686-A1 SULTAM DERIVATIVES ANDERSON KEVIN W 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023541-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS KCNB1, KCNB2, SCNN1B LMNA 611/4885GAA 2499/4885KMT2A 2744/4885
US-20140121213-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS KCNB1, SCNN1B, TRPV1 LMNA 816/4885GAA 1691/4885KMT2A 3151/4885
US-20110124686-A1 SULTAM DERIVATIVES SULT1A1, SULT2A1, SULT1E1 LMNA 4456/4885GAA 1228/4885KMT2A 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.